Potent antitumor efficacy of datopotamab deruxtecan compared with sacituzumab govitecan in an intracranial tumor model of triple-negative breast cancer.
- DOI
- 10.1158/1535-7163.mct-25-1188
- Published
- 2026 Aug 26
- Container
- Molecular cancer therapeutics
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1158/1535-7163.mct-25-1188,
title = {Potent antitumor efficacy of datopotamab deruxtecan compared with sacituzumab govitecan in an intracranial tumor model of triple-negative breast cancer.},
author = {Funasaka C and Takashima H and Okajima D and Maejima T and Yasuda S and Karibe T and Mitsunaga S and Mukohara T and Doi T and Yasunaga M},
year = {2026},
journal = {Molecular cancer therapeutics},
doi = {10.1158/1535-7163.mct-25-1188},
url = {https://doi.org/10.1158/1535-7163.mct-25-1188}
}RIS
TY - JOUR TI - Potent antitumor efficacy of datopotamab deruxtecan compared with sacituzumab govitecan in an intracranial tumor model of triple-negative breast cancer. AU - Funasaka C AU - Takashima H AU - Okajima D AU - Maejima T AU - Yasuda S AU - Karibe T AU - Mitsunaga S AU - Mukohara T AU - Doi T AU - Yasunaga M PY - 2026 JO - Molecular cancer therapeutics DO - 10.1158/1535-7163.mct-25-1188 UR - https://doi.org/10.1158/1535-7163.mct-25-1188 ER -
APA
C, F., H, T., D, O., T, M., S, Y., T, K., S, M., T, M., T, D., & M, Y. (2026). Potent antitumor efficacy of datopotamab deruxtecan compared with sacituzumab govitecan in an intracranial tumor model of triple-negative breast cancer.. Molecular cancer therapeutics. https://doi.org/10.1158/1535-7163.mct-25-1188
Source records
- pubmed · retrieved 2026-09-26T09:47:42.071Z